Cargando…
Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay
Patients with non‐small cell lung cancer (NSCLC) harboring common mutations of the epidermal growth factor receptor (EGFR) are sensitive to EGFR‐tyrosine kinase inhibitors (TKI). Although forms of EGFR harboring single uncommon mutations such as G719X or L861Q are thought to be less sensitive to EGF...
Autores principales: | Kimura, Shinichi, Tanaka, Kentaro, Harada, Taishi, Liu, Renpeng, Shibahara, Daisuke, Kawano, Yuko, Nakanishi, Yoichi, Okamoto, Isamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215868/ https://www.ncbi.nlm.nih.gov/pubmed/30255614 http://dx.doi.org/10.1111/cas.13787 |
Ejemplares similares
-
Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay
por: Ota, Keiichi, et al.
Publicado: (2017) -
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
por: Tanaka, Kentaro, et al.
Publicado: (2017) -
Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014) -
Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low‐dose afatinib: A case report
por: Iida, Yuko, et al.
Publicado: (2019) -
Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
por: Shijubou, Naoki, et al.
Publicado: (2021)